First Header Logo Second Header Logo

Connection

Roger Vilardaga Viera to Humans

This is a "connection" page, showing publications Roger Vilardaga Viera has written about Humans.
Connection Strength

0.464
  1. Rubenstein D, Pacek LR, Smith C, McClernon FJ, Enyioha C, Vilardaga R. Stagnant daily smoking prevalence between 2008 and 2019 among Black and Hispanic adults with serious psychological distress. Drug Alcohol Depend. 2023 Jul 01; 248:109943.
    View in: PubMed
    Score: 0.048
  2. Vilardaga R, McClernon FJ. Regulatory oversight of behavioral digital therapeutics for addiction treatment: A commentary on Khadjesari et al. Addiction. 2021 Dec; 116(12):3287-3289.
    View in: PubMed
    Score: 0.043
  3. Browne J, Halverson TF, Vilardaga R. Engagement with a digital therapeutic for smoking cessation designed for persons with psychiatric illness fully mediates smoking outcomes in a pilot randomized controlled trial. Transl Behav Med. 2021 Sep 15; 11(9):1717-1725.
    View in: PubMed
    Score: 0.043
  4. Vilardaga R, Rizo J, Palenski PE, Mannelli P, Oliver JA, Mcclernon FJ. Pilot Randomized Controlled Trial of a Novel Smoking Cessation App Designed for Individuals With Co-Occurring Tobacco Use Disorder and Serious Mental Illness. Nicotine Tob Res. 2020 Aug 24; 22(9):1533-1542.
    View in: PubMed
    Score: 0.040
  5. Vilardaga R, Rizo J, Ries RK, Kientz JA, Ziedonis DM, Hernandez K, McClernon FJ. Formative, multimethod case studies of learn to quit, an acceptance and commitment therapy smoking cessation app designed for people with serious mental illness. Transl Behav Med. 2019 Nov 25; 9(6):1076-1086.
    View in: PubMed
    Score: 0.038
  6. Luoma JB, Guinther PM, Lawless DesJardins NM, Vilardaga R. Is shame a proximal trigger for drinking? A daily process study with a community sample. Exp Clin Psychopharmacol. 2018 Jun; 26(3):290-301.
    View in: PubMed
    Score: 0.034
  7. Sullivan M, Langford DJ, Davies PS, Tran C, Vilardaga R, Cheung G, Yoo D, McReynolds J, Lober WB, Tauben D, Vowles KE. A Controlled Pilot Trial of PainTracker Self-Manager, a Web-Based Platform Combined With Patient Coaching, to Support Patients' Self-Management of Chronic Pain. J Pain. 2018 Sep; 19(9):996-1005.
    View in: PubMed
    Score: 0.034
  8. Villatte JL, Vilardaga R, Villatte M, Plumb Vilardaga JC, Atkins DC, Hayes SC. Acceptance and Commitment Therapy modules: Differential impact on treatment processes and outcomes. Behav Res Ther. 2016 Feb; 77:52-61.
    View in: PubMed
    Score: 0.029
  9. Vilardaga R, Rizo J, Kientz JA, McDonell MG, Ries RK, Sobel K. User Experience Evaluation of a Smoking Cessation App in People With Serious Mental Illness. Nicotine Tob Res. 2016 May; 18(5):1032-8.
    View in: PubMed
    Score: 0.029
  10. Vilardaga R, Heffner JL, Mercer LD, Bricker JB. Do counselor techniques predict quitting during smoking cessation treatment? A component analysis of telephone-delivered Acceptance and Commitment Therapy. Behav Res Ther. 2014 Oct; 61:89-95.
    View in: PubMed
    Score: 0.026
  11. Cioe PA, Schnoll R, Hoeppner BB, Gross R, Hitsman BL, Leone FT, Ashare R, Vilardaga R, Tashima K, Pinkston M, Kahler CW. The Impact of the COVID-19 Pandemic on Stress, Isolation, Smoking Behaviors, and Motivation to Quit in People with HIV Who Smoke. AIDS Behav. 2023 Jun; 27(6):1862-1869.
    View in: PubMed
    Score: 0.012
  12. Schnoll R, Bernstein SL, Kaufman A, Gross R, Catz SL, Cioe PA, Hitsman B, Marhefka SL, Pacek LR, Vidrine DJ, Vilardaga R, Edelman EJ, McClure JB, Ashare R, Lockhart E, Crothers K. COVID-19 Challenges Confronted by Smoking Cessation Clinical Trials for People Living With HIV: The Experience of Grantees of the US National Cancer Institute. Nicotine Tob Res. 2021 Aug 18; 23(9):1629-1632.
    View in: PubMed
    Score: 0.011
  13. Ashare RL, Bernstein SL, Schnoll R, Gross R, Catz SL, Cioe P, Crothers K, Hitsman B, Marhefka SL, McClure JB, Pacek LR, Vidrine DJ, Vilardaga R, Kaufman A, Edelman EJ. The United States National Cancer Institute's Coordinated Research Effort on Tobacco Use as a Major Cause of Morbidity and Mortality among People with HIV. Nicotine Tob Res. 2021 Jan 22; 23(2):407-410.
    View in: PubMed
    Score: 0.010
  14. Oliver JA, Hallyburton MB, Pacek LR, Mitchell JT, Vilardaga R, Fuemmeler BF, McClernon FJ. What Do Smokers Want in A Smartphone-Based Cessation Application? Nicotine Tob Res. 2018 Nov 15; 20(12):1507-1514.
    View in: PubMed
    Score: 0.009
  15. McDonell MG, Leickly E, McPherson S, Skalisky J, Srebnik D, Angelo F, Vilardaga R, Nepom JR, Roll JM, Ries RK. A Randomized Controlled Trial of Ethyl Glucuronide-Based Contingency Management for Outpatients With Co-Occurring Alcohol Use Disorders and Serious Mental Illness. Am J Psychiatry. 2017 Apr 01; 174(4):370-377.
    View in: PubMed
    Score: 0.008
  16. Karkar R, Zia J, Vilardaga R, Mishra SR, Fogarty J, Munson SA, Kientz JA. A framework for self-experimentation in personalized health. J Am Med Inform Assoc. 2016 May; 23(3):440-8.
    View in: PubMed
    Score: 0.007
  17. Zeng EY, Vilardaga R, Heffner JL, Mull KE, Bricker JB. Predictors of Utilization of a Novel Smoking Cessation Smartphone App. Telemed J E Health. 2015 Dec; 21(12):998-1004.
    View in: PubMed
    Score: 0.007
  18. Lowe JM, McDonell MG, Leickly E, Angelo FA, Vilardaga R, McPherson S, Srebnik D, Roll J, Ries RK. Determining ethyl glucuronide cutoffs when detecting self-reported alcohol use in addiction treatment patients. Alcohol Clin Exp Res. 2015 May; 39(5):905-10.
    View in: PubMed
    Score: 0.007
  19. Leickly E, McDonell MG, Vilardaga R, Angelo FA, Lowe JM, McPherson S, Srebnik D, Roll JM, Ries RK. High levels of agreement between clinic-based ethyl glucuronide (EtG) immunoassays and laboratory-based mass spectrometry. Am J Drug Alcohol Abuse. 2015 May; 41(3):246-50.
    View in: PubMed
    Score: 0.007
  20. Jones HA, Heffner JL, Mercer L, Wyszynski CM, Vilardaga R, Bricker JB. Web-based acceptance and commitment therapy smoking cessation treatment for smokers with depressive symptoms. J Dual Diagn. 2015; 11(1):56-62.
    View in: PubMed
    Score: 0.007
  21. Heffner JL, Vilardaga R, Mercer LD, Kientz JA, Bricker JB. Feature-level analysis of a novel smartphone application for smoking cessation. Am J Drug Alcohol Abuse. 2015 Jan; 41(1):68-73.
    View in: PubMed
    Score: 0.007
  22. Bricker JB, Mull KE, Kientz JA, Vilardaga R, Mercer LD, Akioka KJ, Heffner JL. Randomized, controlled pilot trial of a smartphone app for smoking cessation using acceptance and commitment therapy. Drug Alcohol Depend. 2014 Oct 01; 143:87-94.
    View in: PubMed
    Score: 0.006
  23. McDonell M, McPherson S, Vilardaga R, Srebnik D, Angelo FN, Leickly E, Saxon AJ, Roll J, Ries R. Preliminary findings: Contingency management targeting psycho-stimulant use results in secondary decreases in smoking for severely mentally ill adults. Am J Addict. 2014; 23(4):407-10.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.